Form 4: Beta Bionics CFO Stephen Feider Reports Stock Option Grants
SEC Form 4 Filing
Beta Bionics' Chief Financial Officer, Stephen Feider, reported the acquisition of multiple employee stock options on January 31, 2025.
Summary
- Stephen Feider, the Chief Financial Officer of Beta Bionics, reported the acquisition of employee stock options on January 31, 2025.
- These options include 166,542 shares at an exercise price of $7.51, vesting over time from August 1, 2022.
- Additionally, 109,695 shares were granted at an exercise price of $5.1, vesting from September 14, 2023.
- A further 186,203 shares were granted at an exercise price of $17, vesting monthly from January 29, 2025.
- All options are for common stock and were converted from Class B common stock upon the company's IPO.
Sentiment
Score: 7
Explanation: The document is a routine filing related to executive compensation. It is a neutral event, but positive in that it aligns management with shareholders.
Positives
- The granting of stock options to the CFO aligns his interests with the company's long-term success.
- The vesting schedules encourage long-term commitment from the CFO.
Industry Context
This is a standard SEC Form 4 filing, which is common for publicly traded companies when executives receive stock options. It is a routine part of corporate governance and transparency.
Comparison to Industry Standards
- Stock option grants are a common form of compensation for executives in publicly traded companies, particularly in the technology and biotech sectors.
- The vesting schedules described are typical, with vesting periods ranging from one to four years.
- The exercise prices are set at the time of grant and are often based on the company's stock price at that time.
Stakeholder Impact
- The stock option grants may have a minor positive impact on shareholder sentiment as it aligns the CFO's interests with the company's performance.
Key Dates
| Date | Description |
|---|---|
| 08/01/2022 | Start date for vesting of the first tranche of options. |
| 09/14/2023 | Start date for vesting of the second tranche of options. |
| 01/29/2025 | Start date for vesting of the third tranche of options. |
| 01/31/2025 | Date of the reported stock option grants. |
| 02/03/2025 | Date the Form 4 was signed. |
| 07/31/2032 | Expiration date for the first tranche of options. |
| 09/13/2033 | Expiration date for the second tranche of options. |
| 01/28/2035 | Expiration date for the third tranche of options. |
Keywords
stock options, employee stock options, insider trading, form 4, beneficial ownership, Beta Bionics, BBNX, Stephen Feider, CFO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.